|Application:||Gene expression microarray analysis|
|Number of samples:||24|
|Release date:||Nov 21 2011|
|Last update date:||Aug 23 2018|
|Diseases:||Neoplasms, Neoplastic Syndromes, Hereditary, Lymphoma, B-Cell, Neoplasms, Second Primary|
|Dataset link||Expression data from treatment-induced senescence in mouse Emu-myc B-cell lymphoma model|
Primary lymphoma cells isolated from lymph nodes of Emu-Myc transgenic mice were used. In this model the the c-Myc oncogene is constitutively expressed in the cells of B-cell lineage, leading to spontaneous development of aggressive B-cell lymphomas, resembling Burkitt lymphoma in humans. In order to bring up the senescence as the main failsafe mechanism, primary lymphoma cells are protected from apoptosis by retroviral over-expression of a strong antiapoptotic protein Bcl2. These cells (Myc;Bcl2) massively undergo senescence upon DNA-damaging treatment. Adriamycin (ADR) is a cytostatic drug, used as a standard part of several lymphoma treatment regimens. In this study, transcriptional profiles of matched pairs of untreated vs. 5 days ADR treated Myc;Bcl2 lymphomas were analysed.